How deploying your proceeds into diversified, liquid assets can grow your wealth significantly — with far less concentration risk than keeping everything tied to a single practice.
You've built a physical therapy practice that generates real cash flow and commands a meaningful enterprise valuation. But once your transaction closes, the most consequential financial decision of your life begins — not ends. What you do with your proceeds in the years immediately following a sale will determine whether your liquidity event compounds into generational wealth or simply sits idle. This whitepaper walks through the mathematics of compound growth, compares broad market equity deployment against concentrated practice equity ownership, and illustrates why time — not timing — is the most powerful force in your financial life.
Simple interest pays you a return on your original investment. Compound interest pays you a return on your original investment plus all the returns you've already earned. Over short timeframes, the difference is modest. Over decades, it becomes the difference between comfortable and extraordinary wealth.
At a 10% annual return — roughly the S&P 500's long-run average — $1 million invested today becomes $2.59 million in 10 years, $6.73 million in 20 years, and $17.45 million in 30 years. You contributed nothing additional. Time did the work.
Divide 72 by your annual return rate and you get the approximate number of years it takes for your money to double. At the S&P 500's historical average of 10%, your money doubles approximately every 7.2 years.
A seller who closes at age 50 and invests $3M at 10% will see that capital double to $6M by age 57 — and again to $12M by 64, and $24M by age 71 — without touching a scalpel or a billing system.
Divide by your rate
of return to find your
doubling period
Notice how the growth curve accelerates sharply in the final decade. In the first 10 years, $3M grows by $4.8M. In years 20–30 alone, it grows by over $32M. This is the exponential nature of compounding — the longer the timeline, the more dramatic the acceleration. Sellers who act early and stay disciplined benefit disproportionately from this compounding tail.
| Year | Portfolio Value | Total Gain | Interest Earned That Year | Cumulative Gain % |
|---|---|---|---|---|
| Start | $3,000,000 | — | — | — |
| Year 1 | $3,300,000 | $300,000 | $300,000 | 10% |
| Year 2 | $3,630,000 | $630,000 | $330,000 | 21% |
| Year 3 | $3,993,000 | $993,000 | $363,000 | 33% |
| Year 5 | $4,831,530 | $1,831,530 | $439,230 | 61% |
| Year 7 (1st doubling) | $5,846,853 | $2,846,853 | $531,468 | 95% |
| Year 10 | $7,781,227 | $4,781,227 | $707,384 | 159% |
| Year 12 | $9,415,285 | $6,415,285 | $855,935 | 214% |
| Year 14 (2nd doubling) | $11,392,495 | $8,392,495 | $1,035,681 | 280% |
| Year 15 | $12,531,745 | $9,531,745 | $1,139,250 | 318% |
| Year 20 | $20,181,811 | $17,181,811 | $1,835,619 | 573% |
| Year 21 (3rd doubling) | $22,199,992 | $19,199,992 | $2,018,174 | 640% |
| Year 25 | $32,501,334 | $29,501,334 | $2,954,667 | 983% |
| Year 28 | $43,262,981 | $40,262,981 | $3,932,998 | 1,342% |
| Year 29 (4th doubling est.) | $47,589,279 | $44,589,279 | $4,326,298 | 1,486% |
| Year 30 | $52,348,207 | $49,348,207 | $4,758,928 | 1,645% |
Sitting in cash for five years after a $3M exit — a common outcome for sellers who delay financial planning — costs nearly $20M in terminal wealth over a 30-year horizon. That is not a modest opportunity cost; it is a second liquidity event's worth of value, forfeited to inaction. The single most powerful deployment decision is timing: not which ETF to choose, not which brokerage to use, but when. The answer is always as soon as practicable after close.
Even at a conservative 7% real return — fully accounting for inflation — $3M becomes $22.8M in real purchasing power over 30 years. That is still a 7.6× increase in what your wealth can actually buy. By comparison, a PT practice generates operating income that must be re-earned each year through clinical operations and is subject to all the concentration risks described in Section 5. The real-return comparison still strongly favors disciplined, diversified equity deployment.
Gains on ETF shares held longer than one year are taxed at preferential LTCG rates — 0%, 15%, or 20% federal depending on taxable income — rather than ordinary income rates that can reach 37%. Most sellers with meaningful proceeds will pay 15–20% federal LTCG on realized gains, versus 37% on W-2 income. This is the same favorable rate structure that benefits you at your practice sale closing.
Unlike active mutual funds, broad market ETFs use an in-kind creation/redemption mechanism that rarely generates taxable capital gains distributions to shareholders. This means you generally do not owe capital gains tax in any given year unless you choose to sell shares. Your compounding runs on the full pre-tax amount until you decide to recognize gains — a significant structural advantage over actively managed funds.
An additional 3.8% NIIT applies to investment income (including ETF capital gains and dividends) for taxpayers with modified adjusted gross income above $200,000 (single) or $250,000 (married filing jointly). Sellers with significant proceeds should plan for NIIT applicability in years they realize gains. This does not eliminate the tax advantage of ETFs — it reduces it modestly and applies equally to other investment income.
Holding ETFs inside tax-advantaged accounts (IRA, SEP-IRA, Solo 401(k)) eliminates annual tax drag entirely — all compounding is deferred until withdrawal. In taxable accounts, tax-loss harvesting during market downturns allows sellers to realize losses that offset future gains. These strategies, used together, can meaningfully improve after-tax outcomes beyond what the nominal figures in this document illustrate.
A single S&P 500 ETF share gives you proportional ownership in 500 companies across 11 sectors. Achieving equivalent diversification through individual stock selection would require tens of thousands of dollars in transaction costs and constant rebalancing — with no evidence of better returns. ETFs deliver institutional-grade diversification at retail-accessible cost.
Decades of academic research — including landmark studies by Sharpe, Fama, and French — consistently shows that over 80–90% of actively managed funds underperform their benchmark index over 15+ year periods, net of fees. A seller deploying into a low-cost S&P 500 ETF eliminates manager selection risk entirely and captures the full market return.
ETF holdings are disclosed daily. You know exactly what you own at every moment. Shares trade on exchanges during market hours — no redemption periods, no lock-ups, no gates. If your circumstances change, you can liquidate fully within a single trading day. This is the opposite of your experience as a practice owner, where your equity had no market and no exit until a buyer was found.
Unlike private equity funds or wealth management platforms that often require $1M+ minimums, multi-year commitments, or ongoing advisory relationships, broad market ETFs have no minimum investment, no lock-up period, and no required advisory relationship. A seller can invest $500,000 or $5M with equal access to the same instrument at the same cost.
This whitepaper is not an argument against working with a financial advisor. A fee-only fiduciary advisor — one compensated by a flat fee or hourly rate rather than a percentage of assets under management — can provide meaningful value in tax planning, estate structuring, Social Security optimization, and behavioral coaching during market downturns. The argument here is specifically against AUM-based fee structures on passive index holdings, which charge 1–1.5% annually for a service that requires minimal ongoing management. If you choose to work with an advisor, ensure they are a registered fiduciary, understand their fee structure completely, and ask whether a flat-fee or hourly arrangement would serve your goals equally well at significantly lower total cost.
Decades of academic research shows that time in the market dramatically outperforms market timing. A seller who waits 12 months for "the right entry point" often sacrifices the first full compounding cycle. Lump-sum deployment has historically outperformed dollar-cost averaging in approximately two-thirds of historical periods.
An advisor charging 1% annually on a $5M portfolio costs you $50,000 in year one — but that same dollar compounding at 10% would become $87,000 over 10 years. Low-cost index ETFs (VOO, IVV, SCHB) charge 0.03%–0.05% annually. The difference between a 1% fee and a 0.05% fee on $5M over 30 years exceeds $19M in lost compounding.
Proceeds deployed inside a SEP-IRA, Solo 401(k), or Roth conversion ladder grow without annual tax drag. A traditional brokerage account at 10% gross return may net only 8–8.5% after capital gains distributions. Over 30 years, a 1.5% net return advantage on $3M adds approximately $17M in additional terminal wealth.
Many sellers, energized by liquidity, quickly reinvest in a new practice or buy equity in another operator's platform. This recreates the identical concentration risk you just exited. If operational involvement is desired, consider minority PE equity structures — but ensure the core nest egg remains in diversified, liquid public equities.
S&P 500 ETFs distribute approximately 1.3–1.5% in annual dividends. Automatically reinvesting those dividends means you're continuously buying additional shares that themselves compound. Over 30 years, dividends reinvested account for approximately 40% of the S&P 500's total return — not reinvesting them materially impairs the outcome illustrated in this whitepaper.
The S&P 500 has experienced approximately 27 bear markets (declines of 20%+) since 1928, and recovered from every single one. Long-term investors who remained invested through 2008–09, 2020, and other crashes dramatically outperformed those who sold. Volatility is temporary. The inability to sell a practice during a PE freeze is true illiquidity risk. Broad equities give you both the long-run return and the option to exit any day the market is open.
A well-structured exit from your physical therapy practice is one of the most significant wealth events of your professional life. But the proceeds from that event, deployed intelligently into broadly diversified, low-cost public equities, can multiply many times over across the following decades — with dramatically less concentration risk, zero operational burden, and full liquidity at every step. Compound interest does not require you to see one more patient, sign one more payer contract, or manage one more employee. It only requires time — and the discipline to let it work.
347-878-2941
Confidential consultation, no retainer required
info@mihamainc.com
We respond within one business day
www.mihamainc.com
Resources, case studies & transaction experience